文献速递临床微生物分子诊断质量管理与危急值

基于葡萄糖代谢监测的耐药大肠埃希菌和克雷伯菌快速药敏试验

Rapid susceptibility testing of multi-drug resistant Escherichia coli and Klebsiella by glucose metabolization monitoring.
PubMed 文献 · Clin Chem Lab Med · 2019-01-01

该研究开发了一种名为L-AST的快速药敏方法,通过监测细菌在含抗生素的葡萄糖Luria肉汤中的葡萄糖利用动态来判定敏感性。对178株革兰阴性菌(来自琼脂平板136株和阳性血培养42株)的验证显示,L-AST与常规药敏高度一致(极重大错误<1%,重大错误3.51%),且结果比常规方法提前34小时获得。该方法可在临床化学分析仪上运行,适合整合到实验室常规中实现全天候药敏检测。

要点

  • L-AST可在MALDI-TOF MS鉴定后90-150分钟内提供关键耐药信息。
  • 与常规药敏相比,L-AST的极重大错误<1%,重大错误3.51%。
  • 对42例临床样本,L-AST结果比常规药敏提前34小时获得。

核心结论

  • L-AST可显著加速MALDI-TOF MS鉴定后的药敏检测,是一种简单、低成本、可整合到临床实验室的方法。

研究设计与样本

  • 方法学验证研究,纳入革兰阴性分离株(大肠埃希菌和克雷伯菌属)共178株,其中136株来自琼脂平板单菌落,42株直接来自阳性血培养并经MALDI-TOF MS鉴定。

主要发现

  • L-AST与常规药敏结果高度一致,178株分离株中极重大错误<1%,重大错误3.51%。
  • L-AST可在MALDI-TOF MS鉴定后90-150分钟内提供关键耐药信息。
  • 对42例临床样本,L-AST结果比常规药敏提前34小时获得。

关键数值与推荐

  • L-AST在含单一抗生素(头孢他啶、哌拉西林、亚胺培南、环丙沙星)的葡萄糖补充Luria肉汤中定量测定葡萄糖利用动态以判定敏感性。

临床怎么用

  • L-AST可运行于临床化学分析仪并整合到实验室常规,实现24/7药敏检测,有望改善抗生素治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background The increasing number of multi-drug resistant (MDR) bacteria provides enormous challenges for choosing an appropriate antibiotic therapy in the early phase of sepsis. While bacterial identification has been greatly accelerated by the introduction of matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS), the antibiotic susceptibility testing (AST) remains time-consuming. Here, we present a rapid susceptibility testing method for testing Gram-negative bacteria, exemplarily validated for Escherichia coli and Klebsiella spp. Methods Gram-negative isolates (E. coli and Klebsiella spp.) were either taken as single colonies from agar plates (n=136) or directly extracted and identified from positive blood cultures (n=42) using MALDI-TOF MS. Bacteria were incubated in glucose-supplemented Luria broths (LBs) each containing one antibiotic (ceftazidime, piperacillin, imipenem and ciprofloxacin), routinely used to classify Gram-negative bacteria in Germany. To determine susceptibility the dynamics of glucose utilization in bacterial suspensions were quantitatively measured in the presence or absence of antibiotics designated liquid-AST (L-AST). Results The L-AST can be run on clinical-chemistry analyzers and integrated into laboratory routines. It yields critical resistance information within 90-150 min downstream of a MS-based identification. The results showed a high concordance with routine susceptibility testing, with less than 1% very major errors (VME) and 3.51% major errors (ME) for 178 assessed isolates. Analysis of turnaround time (TAT) for 42 clinical samples indicated that L-AST results could be obtained 34 h earlier than the routine results. Conclusions As exemplified for E. coli and Klebsiella spp., L-AST provides substantial acceleration of susceptibility testing following MALDI-TOF MS identification. The assay is a simple and low-cost method that can be integrated into clinical laboratory to allow for 24/7 AST. This approach could improve antibiotic therapy.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Kittel M, Findeisen P, Ghebremedhin B, et al. Rapid susceptibility testing of multi-drug resistant Escherichia coli and Klebsiella by glucose metabolization monitoring. Clin Chem Lab Med. 2019. PMID: 30763260. doi:10.1515/cclm-2018-1178

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。